262
Views
7
CrossRef citations to date
0
Altmetric
Reviews

Pemetrexed disodium in ovarian cancer treatment

, MD, , MD, , MD, , MD & , MD PhD
Pages 437-449 | Published online: 13 Feb 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Rowan E Miller & Susana Banerjee. (2013) The current state of pemetrexed in ovarian cancer. Expert Opinion on Investigational Drugs 22:9, pages 1201-1210.
Read now

Articles from other publishers (6)

Monika Gulia, Suchitra Nishal, Balaji Maddiboyina, Rohit Dutt, Prasanna Kumar Desu, Rubina Wadhwa & Vikas Jhawat. (2023) Physiological Pathway, diagnosis and nanotechnology based treatment strategies for ovarian Cancer: A review. Medicine in Omics 8, pages 100020.
Crossref
Tomoko Akahane, Akira Hirasawa, Issei Imoto, Aki Okubo, Manabu Itoh, Yoshiko Nanki, Tomoko Yoshihama, Eichiro Tominaga & Daisuke Aoki. (2019) Establishment and characterization of a new malignant peritoneal mesothelioma cell line, KOG-1, from the ascitic fluid of a patient with pemetrexed chemotherapy resistance. Human Cell 33:1, pages 272-282.
Crossref
Michael Roche, Laura Parisi, Linda Li, Amy Knehans, Rebecca Phaeton & Joshua P. Kesterson. (2018) The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review. Oncology Reviews 12:1.
Crossref
CHEN YANG, XIAOJUAN HE, XIAOMIN LIU, ZHENG TANG & XIAOQIU LIANG. (2015) OSTP as a novel peptide specifically targeting human ovarian cancer. Oncology Reports 34:2, pages 972-978.
Crossref
Josefine Reber, Stephanie Haller, Christopher P. Leamon & Cristina Müller. (2013) 177Lu-EC0800 Combined with the Antifolate Pemetrexed: Preclinical Pilot Study of Folate Receptor Targeted Radionuclide Tumor Therapy. Molecular Cancer Therapeutics 12:11, pages 2436-2445.
Crossref
Cristina Müller, Josefine Reber, Claudia Schlup, Christopher P. Leamon & Roger Schibli. (2013) In Vitro and in Vivo Evaluation of an Innocuous Drug Cocktail To Improve the Quality of Folic Acid Targeted Nuclear Imaging in Preclinical Research. Molecular Pharmaceutics 10:3, pages 967-974.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.